High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2–8-year follow-up

Koutrouvelis, Panos G.; Gillenwater, Jay Y.; Lailas, Niko; Hendricks, Fred; Katz, Stuart; Sehn, James; Gil-Montero, Guillermo; Khawand, Nabil

doi:10.1016/s0167-8140(03)00079-3

Cited by 10 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of T3 cancer treated by surgery was, however, small in this study. Only five studies, comprising a relatively small number of patients (≤ 80), reported results of the combination of EBRT and brachytherapy (BT) [47–50] or the use of BT only [51] for T3b PCa. Despite technique considerations with difficulties to ensure needles to the distal parts of SV, more than 80% of the entire SV volume received a dose escalation [48].…”

Section: Discussionmentioning

confidence: 99%

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis

et al. 2019

View full text Add to dashboard Cite

ObjectivesNo study has reported clinical results of external-beam radiotherapy specifically for T3b prostate cancer. The possibility of escalating the dose to the involved seminal vesicles (ISV) while respecting the dose constraints in the organs at risk is thus so far not clearly demonstrated. The objective of the study was to analyze the dose distribution and the clinical outcome in a large series of patients who received IMRT for T3b prostate cancer.Materials and methodsThis retrospective analysis included all patients who received IMRT and androgen deprivation therapy for T3b prostate cancer, between 2008 and 2017, in six French institutions, with available MRI images and dosimetric data.ResultsA total of 276 T3b patients were included. The median follow-up was 26 months. The median (range) prescribed doses (Gy) to the prostate and to the ISV were 77 (70–80) and 76 (46–80), respectively. The dose constraint recommendations were exceeded in less than 12% of patients for the rectum and the bladder. The 5-year risks of biochemical and clinical recurrences and cancer-specific death were 24.8%, 21.7%, and 10.3%, respectively. The 5-year risks of local, pelvic lymph node, and metastatic recurrences were 6.4%, 11.3%, and 15%, respectively. The number of involved lymph nodes (≤ 2 or ≥ 3) on MRI was the only significant prognostic factor in clinical recurrence (HR 9.86) and death (HR 2.78). Grade ≥ 2 acute and 5-year late toxicity rates were 13.2% and 12% for digestive toxicity, and 34% and 31.5% for urinary toxicity, respectively. The dose to the pelvic lymph node and the age were predictive of late digestive toxicity.ConclusionIMRT for T3b prostate cancer allows delivery of a curative dose in the ISV, with a moderate digestive toxicity but a higher urinary toxicity. Lymph node involvement increases the risk of recurrence and death.

show abstract

Section: Discussionmentioning

confidence: 99%

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Moreover, due to the ageing population, an increase of 1-1.5% yearly in cancer cases is expected in the next two decades [2][3][4] . Most of them will receive radiotherapy, and the use of brachytherapy as a radical or palliative treatment has increased due to several factors: the dissemination of pulsed dose rate and high dose rate afterloading machines and the use of new planning systems [5][6][7][8][9][10][11][12][13][14][15][16][17][18] . For instance, in the case of treatment for localised prostate cancer, modern brachytherapy has been added over the past decade.…”

Section: Introductionmentioning

confidence: 99%

Patterns of Care for Brachytherapy in Europe, in Spain and Italy: Comparative Results

Guedea

Ventura

Marchetti

et al. 2007

Tumori

View full text Add to dashboard Cite

Although the estimated workload of the radiation oncologists, physicists and radiation technologists was higher in Spain, no statistically significant differences were found in the average number of patients per center for the following tumor sites: bronchus, head and neck, intracoronary, esophagus, prostate, rectum and skin. Several differences in the use of the brachytherapy procedures applied were also found.

show abstract

“…We have published our results in several journals (1,2). In the first stage, we place the needle with stylet into the target.…”

mentioning

confidence: 99%

Letter to the editor

Koutrouvelis¹

2004

Brachytherapy

View full text Add to dashboard Cite

High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2–8-year follow-up

Cited by 10 publications

References 24 publications

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis

Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis

Patterns of Care for Brachytherapy in Europe, in Spain and Italy: Comparative Results

Letter to the editor

Contact Info

Product

Resources

About